Underlying this observation, expression of the endogenous mTOR inhibitor, DEPTOR, was increased by nearly 900% (296 vs. 2874 A.U. p < 0.05) in E-Stim perfusate treated cells over Non-Stim treated groups, suggesting that E-Stim perfusate slows anabolism in MCF7 breast cancer via action on the mTOR signaling cascade. Here, MTOR is linked to breast carcinoma.